Articles with public access mandates - Brian Dennis LichtyLearn more
Not available anywhere: 7
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
MC Bourgeois-Daigneault, DG Roy, AS Aitken, N El Sayes, NT Martin, ...
Science translational medicine 10 (422), eaao1641, 2018
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Ontario …
Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand
KL Mossman, MF Mian, NM Lauzon, CL Gyles, B Lichty, R Mackenzie, ...
The Journal of Immunology 181 (10), 6702-6706, 2008
Mandates: Canadian Institutes of Health Research
Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen
BW Bridle, J Li, S Jiang, R Chang, BD Lichty, JL Bramson, Y Wan
The Journal of Immunology 184 (8), 4269-4275, 2010
Mandates: Canadian Institutes of Health Research
Purification of therapeutic adenoviruses using laterally-fed membrane chromatography
K Kawka, P Madadkar, U Umatheva, S Shoaebargh, MFC Medina, ...
Journal of Membrane Science 579, 351-358, 2019
Mandates: Natural Sciences and Engineering Research Council of Canada
Consecutive spray drying to produce coated dry powder vaccines suitable for oral administration
DA LeClair, ED Cranston, BD Lichty, Z Xing, MR Thompson
ACS Biomaterials Science & Engineering 4 (5), 1669-1678, 2018
Mandates: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy
DG Roy, AT Power, MC Bourgeois-Daigneault, T Falls, L Ferreira, A Stern, ...
Journal of Controlled Release 220, 210-221, 2015
Mandates: Canadian Institutes of Health Research, Ontario Institute for Cancer Research
Detection of tumor antigen-specific T-cell responses after oncolytic vaccination
JG Pol, BW Bridle, BD Lichty
Oncolytic Viruses, 191-211, 2020
Mandates: Ontario Institute for Cancer Research
Available somewhere: 62
Immunological considerations for COVID-19 vaccine strategies
M Jeyanathan, S Afkhami, F Smaill, MS Miller, BD Lichty, Z Xing
Nature Reviews Immunology 20 (10), 615-632, 2020
Mandates: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Going viral with cancer immunotherapy
BD Lichty, CJ Breitbach, DF Stojdl, JC Bell
Nature Reviews Cancer 14 (8), 559-567, 2014
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Ontario …
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
S Afkhami, MR D’Agostino, A Zhang, HD Stacey, A Marzok, A Kang, ...
Cell 185 (5), 896-915. e19, 2022
Mandates: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Targeting tumor vasculature with an oncolytic virus
CJ Breitbach, NS De Silva, TJ Falls, U Aladl, L Evgin, J Paterson, YY Sun, ...
Molecular Therapy 19 (5), 886-894, 2011
Mandates: Canadian Institutes of Health Research, Ontario Institute for Cancer Research
Potentiating cancer immunotherapy using an oncolytic virus
BW Bridle, KB Stephenson, JE Boudreau, S Koshy, N Kazdhan, ...
Molecular Therapy 18 (8), 1430-1439, 2010
Mandates: Canadian Institutes of Health Research
Maraba virus as a potent oncolytic vaccine vector
JG Pol, L Zhang, BW Bridle, KB Stephenson, J Rességuier, S Hanson, ...
Molecular therapy 22 (2), 420-429, 2014
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Ontario …
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity
CS Ilkow, M Marguerie, C Batenchuk, J Mayer, D Ben Neriah, ...
Nature medicine 21 (5), 530-536, 2015
Mandates: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Synergistic interaction between oncolytic viruses augments tumor killing
F Le Boeuf, JS Diallo, JA McCart, S Thorne, T Falls, M Stanford, F Kanji, ...
Molecular Therapy 18 (5), 888-895, 2010
Mandates: Canadian Institutes of Health Research
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus
BW Bridle, JE Boudreau, BD Lichty, J Brunellière, K Stephenson, S Koshy, ...
Molecular therapy 17 (10), 1814-1821, 2009
Mandates: Canadian Institutes of Health Research
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy
BW Bridle, L Chen, CG Lemay, JS Diallo, J Pol, A Nguyen, A Capretta, ...
Molecular Therapy 21 (4), 887-894, 2013
Mandates: Canadian Institutes of Health Research, Ontario Institute for Cancer Research
Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy
ST Workenhe, G Simmons, JG Pol, BD Lichty, WP Halford, KL Mossman
Molecular Therapy 22 (1), 123-131, 2014
Mandates: Canadian Cancer Society
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine
CG Lemay, JL Rintoul, A Kus, JM Paterson, V Garcia, TJ Falls, L Ferreira, ...
Molecular Therapy 20 (9), 1791-1799, 2012
Mandates: Canadian Institutes of Health Research, Ontario Institute for Cancer Research
VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection
R Arulanandam, C Batenchuk, FA Angarita, K Ottolino-Perry, ...
Cancer Cell 28 (2), 210-224, 2015
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Natural …
Publication and funding information is determined automatically by a computer program